Introduction
The function of natural killer (NK) cells is regulated by a balance between inhibitory and activating signals transmitted through respective receptors. 1 Inhibitory ones include killer cell Ig-like receptors (KIRs) and lectin-like heterodimer NKG2A:CD94. KIRs are specific for HLA class I molecules, namely KIR2DL1 binds HLA-C (group 2), KIR2DL2/3 recognizes HLA-C (group 1), while KIR3DL1 is specific for HLA-Bw4. NKG2A:CD94 has a broad class I specificity, as it recognizes leader peptides of most HLA-A, -B and -C molecules in the context of ubiquitous HLA-E. 1 The distribution of inhibitory receptors is clonal, which leads to formation of a large spectrum of receptor expression among NK cells. The NK cell receptor repertoire is individual and determined mainly by KIR genotype, with a subtle modifying effect of HLA class I. 2, 3 In an animal model, Ruggeri et al. 4 showed that if a recipient of an HLA-mismatched allogeneic hematopoietic SCT (allo-HSCT) lacks ligand to one of donor inhibitory KIRs, donor-derived NK cells may show alloreactivity resulting in beneficial GVL effect independent on GVHD. In a setting of haploidentical HSCT, KIR-ligand incompatibility in graft-vs-host direction was shown to reduce the risk of relapse and improve survival of patients with acute myeloid leukemia. 4 The beneficial effect of KIR-ligand mismatch was confirmed in some other series of haploidentical HSCT, cord blood transplantations as well as unrelated donor (URD)-HSCT. [4] [5] [6] [7] [8] In contrast, a number of retrospective studies did not confirm these results, reporting equal or even inferior outcome for patients given transplants from KIR-ligand-mismatched donors. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] This inconsistency of clinical results was postulated to be a consequence of heterogeneity regarding transplantation procedures. 19 In particular, the extent of T-cell depletion, CD34
þ cell dose and intensity of post transplant immunosuppression were discussed to influence recovery of NK cell as well as their potential to show alloreactivity after allo-HSCT.
Reconstitution of the NK cell receptor repertoire was a subject of three studies on haploidentical HSCT, showing functional immaturity of NK cells, associated with an overexpression of NKG2A:CD94 and low frequency of KIR þ cells. [21] [22] [23] In a setting of an HLA-matched allo-HSCT, Shilling et al. 24 showed that after transplantation, the NK cell phenotype tends to recapitulate the donor type. The investigators noticed that slower recovery was associated with the incidence of relapse and severe immunerelated complications. Unfortunately, limited number of patients did not allow detailed statistical analysis of factors influencing the process. In another study, Cooley et al. 20 showed that on day þ 100, KIR expression is lower for patients treated with unmanipulated BM compared with T-cell depleted allografts suggesting a modifying effect of T-cell dose on NK cell recovery. In that study, however, neither the effect of immune suppression or GVHD was analyzed.
In this study, we prospectively evaluated reconstitution of NK cell receptor repertoire after KIR-ligand-matched allo-HSCT. Our aim was to determine factors that influence NK cell phenotypic maturation, which, in turn, could be important for prediction of beneficial NK cell alloreactivity.
Materials and methods

Patients and donors
Eighty-three consecutive adult patients with hematological malignancies treated with allo-HSCT between January 2005 and December 2006 in the Department of Hematology and Bone Marrow Transplantation of the Silesian Medical University in Katowice, Poland were prospectively enrolled in the study (Table 1 ). The median recipient age was 31 years (range, 18-58) and the diagnoses were as follows: acute myeloid leukemia (n ¼ 32), chronic myeloid leukemia (n ¼ 28), acute lymphoblastic leukemia (n ¼ 19), myelodysplastic syndrome (n ¼ 1) and Hodgkin's lymphoma (n ¼ 1). Disease status at allo-HSCT was classified as early (first CR or chronic phase, n ¼ 63) or advanced (n ¼ 20). The donors were either HLA-identical siblings (n ¼ 32) or unrelated volunteers (n ¼ 51). Related donors were selected based on evaluation of HLA-A, -B, -C, -DRB1, and -DQB1 using DNA low-resolution technique, whereas in case of URDs high-resolution typing for both HLA class I and class II loci was performed. URD-HSCT full compatibility (10 out of 10 loci) was established in 39 cases while in the remaining 12 donor-recipient pairs a single mismatch in either HLA-B (n ¼ 2), -C (n ¼ 5), or -DQB1 (n ¼ 5) was accepted. Patients for whom the donors were KIR-ligand mismatched were not included in the study.
The protocol was approved by the bioethical committee of the Silesian Medical University. In all cases written informed consent was obtained.
Transplantation procedure
Preparative regimen was myeloablative in all patients. In case of ALL TBI (12 Gy) combined with CY (120 mg/kg) was preferentially applied. Patients with myeloid malignancies were treated with either oral BU (16 mg/kg) þ CY (120 mg/kg) or treosulfan 3 Â 14 g/m 2 in combination with fludarabine 5 Â 30 mg/m 2 . The latter regimen had previously been described as having myeloablative potential and favorable toxicity profile. 25, 26 Patients treated with URD-HSCT additionally received antithymocyte globulin, either Thymoglobulin (Genzyme, Cambridge, MA, USA) at the total dose of 6 mg/kg or ATG-Fresenius (Fresenius, Grafelfing, Germany) at the dose of 15-30 mg/kg. BM was used as a source of stem cells in 46 patients while G-CSF stimulated peripheral blood (PB) was used in 37 cases. Hematopoietic growth factors were not routinely used to support neutrophil recovery. Prophylaxis of GVHD consisted of CsA and short-course MTX. Metylprednisolone was used as a first-line therapy of acute GVHD at the initial dose of 0.5-2.0 mg/kg, dependent on the severity of the symptoms. Chronic GVHD was treated with steroids and CsA. In case of steroid resistance mycophenolate mofetil was introduced.
KIR genotyping
All donors were evaluated for the presence of inhibitory KIR genes (KIR2DL1, KIR2DL2, KIR2DL3 and KIR3DL1) and their activating counterparts (KIR2DS1, KIR2DS2, KIR2DS3 and KIR3DS1), as described earlier. 27 Briefly, genomic DNA was isolated from venous blood using Qiagen columns (Qiagen, Hilden, Germany). The presence or absence of KIR genes was determined using locusspecific primers and PCR conditions described elsewhere. 27 All reactions contained an internal positive control consisting of an additional pair of primers specific for the AAT gene (5 0 -CCCACCTTCCCCTCTCTCCAGGCAAA TGGG-3 0 and 5 0 -GGGCCTCAGTCCCAACATGGCTA AGAGGTG-3 0 ).
Sample collection PB (10 ml) was drawn from all donors and recipients before transplantation. After allo-HSCT, sample collection was scheduled on days 28 ( ± 4), 56 ( ± 4), 100 ( ± 7), 180 ( ± 14) and 365 (±30). Samples from all 83 patients were taken on day þ 28, from 81 patients on day þ 56, 76 patients on day þ 100, 65 patients on day þ 180 and 54 patients on day þ 365. Missing samples were mainly because of mortality or disease progression.
Monoclonal antibodies and cytometric analysis
Analysis of NK cell receptors. Monoclonal antibodies: CD158A (EB6B, anti-KIR2DL1/DS1), CD158B (GL183, anti-KIR2DL2/DL3/DS2), CD158E (CD273.7, anti-KIR3DL1/ DS1) and CD159A (Z199, anti-NKG2A), all conjugated with phycoerythrin (PE), purchased from Beckman-Coulter, Miami, FL, USA, were all used in combination with anti CD3 (SK7, Becton Dickinson, San Jose, CA, USA), and CD56 (N901, Beckman-Coulter) in individual threecolor flow cytometry assays of each peripheral whole blood sample. Expression of inhibitory KIRs and NKG2A was evaluated on NK cells, identified by CD3 À CD56 þ gating, using relevant isotype-matched control to exclude the background fluorescence and receptor-negative cells. To avoid procedural reasons of changes in phenotype of cells in serial measurements, equalization methods of sample collection, staining, acquisition and analysis were used. Light scatter and fluorescence parameters of a flow cytometer were daily standardized to ensure optimal instrument performance. All the flow cytometric analyses were performed on EPICS-XL-MCL (Beckman-Coulter).
Analysis of lymphocyte subpopulations. In parallel to NK cells, T cells (CD3
were analyzed in PB, as described earlier. 28 The following monoclonal antibodies were used for this part of the study: CD45-FITC, CD14-PE, CD3-FITC, CD4-PE, CD8-PE, CD19-PE (Beckman Dickinson, San Jose, CA, USA).
Expression of inhibitory KIRs and NKG2A after allo-HSCT As monoclonal antibodies recognized both inhibitory KIRs and their activating counterparts, evaluation of inhibitory KIRs were restricted to patients who possessed genes for KIR2DL1, KIR2DL2/DL3 and KIR3DL1, while were negative for KIR2DS1, KIR2DS2 and KIR3DS1, respectively. In addition, only patients alive and disease-free up to 1 year after allo-HSCT were included in this part of the analysis. Altogether, 26 patients were assessed for expression of KIR2DL1, 30 patients for KIR2DL2/DL3, 31 patients for KIR3DL1 and 52 patients for NKG2A.
Evaluation of KIR and NKG2A phenotypic pattern Individual pattern was created for each patient and his donor based on frequencies of NK cells expressing KIR2DL1/DS1, KIR2DL2-3/DS2, KIR3DL1/DS1 and NKG2A, together with median fluorescence intensity (MFI) for respective receptors. Differences between donor and recipient NK cell phenotype pattern were quantified using a method originally suggested by Shilling et al., 24 and modified for the purpose of this study. The differences were expressed as Discrepancy Index (DI), calculated according to the following formula: The DI was calculated before transplantation and for all time-points after allo-HSCT to evaluate whether the NK cell phenotypic pattern tends to recapitulate the donor one, and to define factors affecting this process.
Study end-points and statistical analysis
Frequencies of inhibitory KIRs and NKG2A expression by NK cells after allo-HSCT were compared with those of the donors using the Wilcoxon test. The effect of clinical factors on receptor expression was analyzed with the use of either Mann-Whitney U-test or Spearman's rank correlation test. The following factors were analyzed: donor and recipient age (continuous variables), donor type (sibling vs unrelated), source of stem cells (BM vs PB), type of conditioning regimen (TBI-based vs chemotherapy-based), CD34
þ and CD3 þ cell dose in the graft (continuous variables), grades II-IV acute GVHD, chronic GVHD and the use of steroids. The same methods were applied to evaluate factors affecting NK cell phenotypic reconstitution, as defined by DI.
For each study time-point the effect of DI (categorized by quartiles) on further outcome was analyzed with regard to the following end-points: OS, disease-free survival, incidence of hematological relapse and non-relapse mortality. OS was the time between transplantation and death because of any cause, whereas disease-free survival was defined as time interval from allo-HSCT to the first event (either hematologic relapse or death in CR). OS and disease-free survival were calculated according to the Kaplan-Meier method, while relapse incidence and nonrelapse mortality were estimated as cumulative incidence, taking into account competing risks. 29 Log-rank tests were used for comparisons.
All tests were two-sided and P-values o.05 were considered statistically significant.
Results
Outcome of allo-HSCT All patients engrafted. With the median follow-up of 29 months, the probabilities of OS and disease-free survival at 2 years equaled 74% (s.e. ±4%) and 71% (±5%). Eleven patients relapsed and 13 patients died of transplant-related complications. The cumulative incidence of relapse and non-relapse mortality was 14% (±4%) and 15% (±4%), respectively. Grades II-IV acute GVHD was diagnosed in 20 cases (cumulative incidence, 24% ± 5%) while chronic GVHD, in 40 out of 78 evaluable patients (cumulative incidence 51% ± 6%). Forty-three patients (52%) received steroids at any time after transplantation for the treatment of either GVHD or other complications.
Expression of KIR2DL1 by NK cells
Median expression of KIR2DL1 by NK cells on day þ 28 was 4.7% (range, 1.1-36.6) and was continuously increasing over the study period reaching 12.6% (range, 0.6-71.6) on day þ 365. However, at all study time-points the frequencies were significantly lower compared with those observed in donors: 20.1% (range, 0-54.4) ( Table 2 and Figure 1a ). MFI for KIR2DL1 was significantly increased on days þ 28 and þ 100 (Table 2) .
On day þ 28, frequency of KIR2DL1 þ NK cells was higher for patients receiving PB compared with BM transplants (6.3% (range, 3-26.6) vs 4% (range, 1.1-14.6), P ¼ 0.02)). Expression of KIR2DL1 correlated positively with the CD34 þ cell dose on days þ 28 (R ¼ Figure 1b) . On day þ 365, the frequency of KIR2DL2/DL3
þ NK cells achieved the donor level, that is, equaled 25.5% (range, 3.6-79.1). MFI for KIR2DL2/DL3 was significantly increased up to day þ 180, and normalized at 1 year after allo-HSCT (Table 2) .
No association was found for the expression of KIR2DL2/DL3 and transplanted cell dose. On day þ 28, the frequency of KIR2DL2/DL3 þ NK cells was higher for patients who developed grades II-IV acute GVHD compared with the remaining patients 
Expression of KIR3DL1 by NK cells
Median frequency of KIR3DL1 þ NK cells on day þ 28 was comparable to that from the donors (16.8% (range, 0-42) vs 14.1% (range, 0-44.6), P ¼ 0.83)) (Table 2, Figure 1c ). At later time-points, the expression of KIR3DL1 was continuously decreasing and starting from Table 2 Expression of inhibitory receptors by NK cells following allo-HSCT day þ 100 it was significantly lower compared with donors. MFI for KIR3DL1 was significantly increased on day þ 28 and comparable to that of donors in later time-points (Table 2) . No correlation was found for KIR3DL1 expression and transplanted cell dose. On day þ 100, the frequency of KIR3DL1 þ NK cells was higher for patients who developed grades II-IV acute GVHD compared with the remaining ones (16.6% (range, 10.9-21.6) vs 11.7% (range, 0-37.3), P ¼ 0.04)). In a post transplant course, the frequency of KIR3DL1 þ NK cells did not correlate with the absolute numbers of PB T cells and their subpopulations.
Expression of NKG2A by NK cells
Median expression of NKG2A by NK cells on day þ 28 equaled 89.9% (range, 45-99.5) and was significantly higher compared with that from the donors (46.8% (16.8-80.7), Po0.0001) (Figure 1d ). Despite continues decrease of NKG2A expression over time the difference remained significant up to day þ 180, while on day þ 365 the median frequency of NKG2A þ NK cells was comparable to that from the donors (51.9% (range, 9.9-79.7)). During the whole study period, MFI for NKG2A was significantly increased ( Table 2) .
The frequency of NKG2A þ NK cells was lower for patients receiving PB compared with BM transplants on days þ 56 (69% (range, 9. On day þ 365, median expression of NKG2A by NK cells was 60.5% (range, 19.9-79.9) for 25 patients who were treated with steroids at any time after allo-HSCT compared with 48.1% (range, 9.9-74.1) for the remaining 27 patients who did not receive steroids (P ¼ 0.04). On day þ 28, the frequency of NKG2A þ NK cells correlated negatively with the absolute number of PB CD3
Reconstitution of NK cell receptor phenotypic pattern
The phenotypic pattern of NK cell receptors was followed after transplantation and compared with that from the donors. The differences were quantified using 'DI' as described in 'Evaluation of KIR and NKG2A phenotypic pattern'. At all study time-points, the values of DI were significantly lower compared with the initial recipientdonor phenotypic pattern difference (Figure 2) . Furthermore, in a post transplant course the values of DI continuously decreased starting from 5.9 (range, 2.4-17) on day þ 28 to 4.1 (range, 0.7-12) on day þ 365. The use of steroids at any time before sample collection was associated with higher values of DI (Figure 3 ). The differences were significant on days þ 56 (5.7 (range, 2.2-12.8) vs 4.5 (range, 1.9-9.5), P ¼ 0.01) and þ 100 (5.2 (range, 1.9-12.1) vs 4.2 (range, 1.8-11.7), P ¼ 0.04). In contrast, none of the other factors, including T-cell dose in the graft and the occurrence of acute and chronic GVHD influenced significantly DI. DI correlated adversely with the absolute number of circulating CD3
On day þ 28, values of DI above median were associated with increased incidence of non-relapse mortality: 24% (95% confidence interval, 14-41%) vs 8% (3-22%), P ¼ 0.03. There was also a tendency to decreased OS in patients with higher DI: 67% (52-81%) vs 81% (68-94%), P ¼ 0.07. No other associations between long-term outcome and DI could be shown.
Discussion
NK cells are the first lymphocyte subpopulation to reconstitute after allo-HSCT and the absolute number of NK cells may exceed that observed in healthy individuals as soon as on day 28 after transplantation. 30 There is evidence that the speed of NK cell recovery correlates with outcome suggesting their important role in the early period when specific immunity represented by T cells is profoundly suppressed. 31 In contrast, NK cells derive from donor stem cells and must follow all steps of ontogeny. Therefore, the high absolute number of these cells does not necessarily translate into their capacity to show all physiological functions. Indeed, as shown earlier, within the first 100 days after allo-HSCT, there is overrepresentation of CD56 bright CD16 neg cells, the subpopulation characterized by limited cytotoxicity, while producing high amounts of IFN-g. 32, 33 Further studies showed increased expression of NKG2A:CD94 and decreased expression of KIRs. [21] [22] [23] [24] As NKG2A:CD94 recognizes most of HLA class I molecules it is assumed that NKG2A:CD94 þ NK cells respond to global changes in HLA expression but not to the absence of specific HLA class I ligands. Hence, only NKG2A: CD94 À KIR þ cells may have potential to show alloreactivity in the case of donor-recipient KIR-ligand incompatibility. 1 In view of the above considerations, prediction of alloreactivity should be considered in the context of NK cell phenotypic maturation and identification of factors affecting this process appears essential.
Reconstitution of NK cell receptor repertoire was the subject of few studies and only two were focused on HLAmatched transplantations. In the one by Shilling et al., 24 including 18 recipients of HLA-identical sibling transplants, the investigators analyzed the NK cell phenotype including both receptor frequencies and receptor density per single cell. Calculating a sum of differences for these two parameters and four analyzed receptors it was shown that NK cells tend to restore the donor phenotype after transplantation. Furthermore, disturbances of this process were associated with severe complications and were suggested to influence outcome. 24 Unfortunately, a limited number of subjects did not allow statistical analysis and elucidation of prognostic factors. In another study, Cooley et al. 20 analyzed the effect of T-cell content in the graft on NK cell phenotype and IFN-g production at approximately 3 months after URD-HSCT. They showed that in patients receiving T-cell depleted transplants, NK cells expressed fewer KIRs and produced more IFN-g compared with those transplanted with unmanipulated BM. Higher IFN-g production was associated with the incidence of acute GVHD. However, as the investigators did not analyze post transplant immunosuppression, it remained unclear whether the effect of T-cell dose was direct or mediated by immune complications and their therapy.
In this study, we extensively evaluated reconstitution of NK cell receptor repertoire in a cohort of KIR-ligandmatched allo-HSCT recipients. The analysis included expression of particular receptors as well as the combined KIR-NKG2A phenotypic pattern. For the first part of the analysis, we focused on inhibitory receptors and therefore only patients who possessed respective genes while lacking their activating counterparts were included. In line with previous reports, we showed that the expression of inhibitory KIRs was generally lower compared with the donors. [21] [22] [23] [24] However, the dynamics of KIR recovery varied among particular receptors. The most prolonged and profound suppression was observed for KIR2DL1, which expression did not reach the donor level during the whole study period. The expression of KIR2DL2/DL3 tended to normalize 6 months after allo-HSCT. In contrast, the frequencies of KIR3DL1 were initially comparable to the donor ones, while decreased significantly starting from day þ 100. This observation corresponds to the in vitro experiments by Fischer et al., 34 showing that the acquisition of HLA-C-specific KIRs is sequential and occurs earlier for KIR2DL2/3 compared with KIR2DL1. The differences in dynamics of inhibitory KIR reconstitution may be essential for prediction of the beneficial NK cell alloreactivity. Therefore, according to our observation the biggest chance for early alloreactivity should be for missing HLA-Bw4, followed by missing HLA-C(1), while it may be difficult to show for missing HLA-C(2).
The analysis of factors influencing KIR expression revealed that the frequency of KIR2DL1 þ NK cells correlated with increased numbers of CD34 þ cells in the graft. Hence, it may be assumed that high cell dose, and especially the use of PB as a source of stem cells may be favorable if NK cell alloreactivity based on missing HLA-C(2) is expected. In contrast, neither cell dose nor other patient, donor and transplant characteristics influenced expression of other KIRs. It is noteworthy that in opposite to the findings of Cooley et al, 20 T cells in the graft had no effect on KIR expression, and the presence of acute GVHD even increased the frequencies of KIR2DL2/DL3 and KIR3DL1 by NK cells. Furthermore, on day þ 28 the expression of KIR2DL2/DL3 correlated with the number of circulating T cells.
In line with previous reports, NKG2A was overexpressed up to 6 months after transplantation. [21] [22] [23] [24] At 1 year it normalized but remained increased for patients receiving steroids. The frequencies of NKG2A by NK cells correlated negatively with both T-cell content in the graft and the number of circulating T cells. These findings correspond to recently published results by Nguyen et al., 35 who showed that less extensive T-cell depletion of the graft was associated with enhanced NKG2A
À NK cell recovery after haploidentical HSCT.
For the analysis of the NK cell phenotypic maturation, we used a method originally suggested by Shilling et al. 24 The differences between donor and recipient pattern were quantified according to a modified formula and defined as DI. We statistically confirmed that the receptor pattern after allo-HSCT tends to recapitulate the donor type although the process is long lasting. We showed that the NK cell phenotypic maturation is negatively affected by the use of steroids in a post transplant course. The differences were significant on days þ 56 and þ 100. Importantly, the incidence of acute and chronic GVHD did not influence significantly the DI and the number of circulating T cells, including both CD4 þ and CD8 þ cells correlated with NK cell phenotypic maturation. Therefore, it appears that neither T cells in the graft nor GVHD itself adversely influence the NK cell receptor reconstitution. In contrast, the use of steroids to treat GVHD and other post transplant complications is critical. This observation corresponds to our previous report showing that the use of steroids for GVHD prophylaxis negatively affects quantitative reconstitution of NK cells after allo-HSCT. 36 Moreover, as shown in clinical models, the use of methylprednisolone has a negative effect on NK cell cytotoxicity and the expression of the major activating receptors, including NKp30 and NKp44. 37 Therefore, results of our study, in the context of previous reports, indicate that the use of steroids should be avoided if NK cell alloreactivity is expected. In contrast, the beneficial effect of KIR-ligand incompatibility should be anticipated only in transplant cohorts with low risk of GVHD and other complications requiring administration of steroids. This theory may explain why survival advantage of KIR-ligand mismatch was so far shown mainly for transplantations with extensive T-cell depletion and young recipient age.
Altogether we showed that: (1) the acquisition of KIRs by NK cells after allo-HSCT is sequential and starts with KIR3DL1, followed by KIR2DL2-3 and KIR2DL1, (2) NKG2A is overexpressed within 6 months after transplantation, (3) NK cell phenotypic pattern tends to recapitulate the donor type, (4) phenotypic maturation of NK cells is disturbed by the use of steroids and (5) T-cell recovery occurs in parallel to NK cell maturation. These findings should facilitate interpretation of retrospective analyses regarding NK cell alloreactivity. They should also be taken into account when trying to predict potential benefit from KIR-ligand incompatibility in prospective studies and in daily practice.
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